A personalized medicine product to predict toxicity to 5-FU-based chemotherapy

TheraGuide 5-FU assesses a persons risk of developing a severe toxic reaction to 5-FU-based chemotherapy. It detects variations in 2 genes, dihydropyrimidine dehydrogenase (DPYD) and thymidylate synthetase (TYMS), that are responsible for a significant portion of serious adverse reactions to 5-FU-based therapy.

Please visit the myriadtests.com website to learn more about how to identify patients at risk for developing 5-FU related toxicity.

Additional Resources

TheraGuide Website for Consumers
TheraGuide Website for Healthcare Professionals